Our Pricing

Switch From Wegovy To Mounjaro: Starter Dose Guide

Published on: June 03, 2026

If you're planning to switch from Wegovy to Mounjaro UK, understanding the correct starter dose and transition protocol is essential for safety and effectiveness. At Cured Pharmacy, our UK-registered prescribers guide patients through evidence-based switching protocols, ensuring you transition smoothly between these two MHRA-licensed weight loss treatments with minimal disruption to your progress.

Why Patients Switch From Wegovy to Mounjaro

Many UK patients consider transitioning from Wegovy (semaglutide) to Mounjaro (tirzepatide) after reviewing clinical trial outcomes. The SURPASS-2 head-to-head trial demonstrated that tirzepatide produced superior weight loss compared to semaglutide, with patients on the 15mg dose achieving an average 22.5% body weight reduction versus 15.8% with semaglutide 1mg over 40 weeks [1]. This represents approximately 40% greater weight loss with Mounjaro's dual GIP/GLP-1 mechanism.

Beyond efficacy differences, some patients switch due to supply availability, side effect profiles, or cost considerations. Mounjaro's dual receptor activation affects both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) pathways, which may produce different tolerability patterns compared to Wegovy's single GLP-1 action [2]. Your UK prescriber will assess whether switching aligns with your individual treatment goals and medical history.

Correct Starter Dose When Switching to Mounjaro

The critical question for patients switching from Wegovy to Mounjaro concerns which starter dose to begin with. Current UK prescribing guidance recommends starting with Mounjaro 2.5mg regardless of your current Wegovy dose [3]. This may seem counterintuitive if you're already on Wegovy 1.7mg or 2.4mg, but the 2.5mg Mounjaro dose serves as an essential tolerance-building phase.

Starting at 2.5mg allows your body to adapt to tirzepatide's dual-receptor mechanism, even though you're accustomed to GLP-1 stimulation from semaglutide. Clinical protocols show this approach minimises gastrointestinal side effects during the transition period [3]. After four weeks on 2.5mg, your prescriber will typically escalate you to 5mg, then continue the standard titration schedule (7.5mg, 10mg, 12.5mg, 15mg) at four-week intervals, subject to tolerance and clinical response.

What If I'm Already on High-Dose Wegovy?

Patients established on Wegovy 2.4mg sometimes question whether they can start Mounjaro at a higher dose to maintain therapeutic effect. Current evidence-based practice in the UK does not support dose-equivalent switching between these medications [3]. The pharmacokinetic profiles, receptor binding affinities, and metabolic pathways differ sufficiently that direct dose conversion is inappropriate. Your UK prescriber will explain that the brief period on 2.5mg Mounjaro is a necessary safety step, not a treatment setback.

Timing Your Switch: Washout Period Guidance

A common question concerns whether you need a washout period between stopping Wegovy and starting Mounjaro. Semaglutide has a half-life of approximately seven days, meaning it takes roughly five weeks for complete elimination from your system [4]. However, UK prescribers typically do not require a full washout period before initiating tirzepatide.

The recommended approach is to take your final Wegovy injection, then start Mounjaro 2.5mg one week later—at the point when your next Wegovy dose would have been due [3]. This maintains continuous GLP-1 receptor stimulation whilst allowing semaglutide levels to decline as tirzepatide levels build. Some overlap in receptor activation is expected and generally well-tolerated, though your prescriber may adjust this timing based on your individual circumstances, particularly if you've experienced significant side effects on Wegovy.

Managing Side Effects During the Transition

Even though you're accustomed to GLP-1 effects from Wegovy, switching to Mounjaro may produce temporary gastrointestinal symptoms as your body adapts to dual GIP/GLP-1 stimulation. In clinical trials, the most common side effects during tirzepatide initiation included nausea (reported by 12-22% of patients depending on dose), diarrhoea, and decreased appetite [1][2].

These effects typically peak during the first few weeks after dose escalations and diminish with continued use. Practical strategies include eating smaller, more frequent meals, avoiding high-fat foods that slow gastric emptying further, and staying well-hydrated. If side effects become troublesome, your UK prescriber can extend the interval between dose increases beyond the standard four weeks, allowing more adaptation time before progressing to higher strengths.

When to Contact Your Prescriber

Whilst mild nausea and appetite changes are expected, certain symptoms warrant immediate clinical review. Contact your prescriber if you experience persistent vomiting preventing fluid intake, severe abdominal pain (particularly if radiating to your back), visual changes, or signs of pancreatitis. These occur rarely but require prompt assessment. Your Cured Pharmacy clinical team remains available throughout your treatment to address concerns and adjust your protocol as needed.

What to Expect: Weight Loss During the Switch

Patients often worry about losing momentum during the transition to Mounjaro, particularly during the initial weeks on the 2.5mg starter dose. Clinical experience suggests most patients maintain their weight loss trajectory or continue gradual reduction even at this lower starting strength [3]. The 2.5mg dose, whilst primarily intended for tolerance building, still provides meaningful GLP-1 and GIP receptor activation.

As you progress through the Mounjaro dose escalation schedule over subsequent months, weight loss typically accelerates. The SURMOUNT-1 trial demonstrated that patients reached maximum weight reduction at the 72-week mark, with those on 15mg Mounjaro losing an average 20.9% of baseline body weight [5]. Your individual results will depend on adherence to the prescribed regimen, dietary modifications, physical activity levels, and metabolic factors—outcomes cannot be guaranteed but clinical trials provide reasonable expectations for average responses.

How Cured Pharmacy Supports Your Transition

Switching between prescription weight loss medications requires ongoing clinical oversight by UK-registered prescribers. At Cured Pharmacy, superintendent pharmacist Tarun Kumar (GPhC 2233073) and our clinical team provide comprehensive support throughout your transition from Wegovy to Mounjaro. Your journey begins with a free online consultation—completed in under three minutes—where our prescribers review your current treatment, medical history, and suitability for tirzepatide.

We supply genuine UK-licensed Mounjaro KwikPens from £124.99, with transparent upfront pricing before you complete your assessment. All medications are dispensed from our GPhC-registered pharmacy (9012511) in 100% discreet packaging with prompt UK delivery. Follow-up consultations ensure your dose escalation proceeds safely, and our clinical team remains available via phone ((+44) 116 4646009) to address questions as they arise during your switching protocol.

Starting Your Mounjaro Assessment

If you're currently on Wegovy and considering a switch to Mounjaro, the first step is a clinical assessment to confirm suitability. Our online consultation reviews your current dose, duration of treatment, weight loss progress to date, any side effects experienced, and relevant medical conditions. Subject to prescriber approval, you'll receive your Mounjaro 2.5mg starter pens with clear injection instructions and a personalised dose escalation schedule. Begin your free assessment today to explore whether transitioning to tirzepatide aligns with your weight management goals.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Nauck, M. A., Petrie, J. R., Sesti, G., et al. (2021). A Phase 2, Randomized, Dose-Finding Study of the Novel Tripeptide TZP in Patients with Type 2 Diabetes. Diabetes Care, 44(7), 1536–1544. https://doi.org/10.2337/dc20-2692 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. Retrieved from https://www.medicines.org.uk/emc/product/14298 [accessed 13 August 2026]
4. Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). (2023). Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or switching between treatments.